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Substance dependence is characterized by 
compulsive substance seeking and high vul-
nerability to relapse. A major challenge in 
current substance addiction research is not 
only to understand the immediate effects of 
substances of abuse on brain operations. It 
is also to define, at the behavioral and neural 
levels, how cognitive, emotional, and moti-
vational processes interact with substance 
use in order to lead to this psychopathologi-
cal state which defines addiction. For the 
last decade, research and progress into the 
biological basis of the addictive process has 
led to a rapidly growing number of phar-
macological agents used to interrupt the 
progress of the addiction pattern, however 
without a significant/adequate impact.
It seems that the abstinent versus sati-
ated states differ significantly (Kalivas 
and Volkow, 2005). Prolonged abstinence 
from substances of abuse is character-
ized by dysphoria, depression, and anxi-
ety, coupled with high stress and craving; 
therefore strongly affecting the quality 
of life. It is speculated that memories of 
habitual substance use, produced by anx-
ious and/or stressful emotional states, may 
have implications for understanding the 
role of learning and memory processes 
in substance addiction (Perrine et al., 
2008; Packard, 2009). Substance depend-
ent individuals, during their withdrawal, 
commonly employ thought-suppression 
to cope with stress and intrusive cogni-
tions about the substance (Garland et al., 
2012). Hence, abstinence-induced stress-
related mood disorders are considered to 
be the main valence to define addiction as 
a chronic brain disorder, and stress is one of 
the major factors in substance seeking and 
relapse to its usage (Lu et al., 2003; Koob 
and Zorrilla, 2010).
Understanding the neurobiological 
basis of the abstinent state is a necessity 
to adequately treat substance relapse. The 
development of addiction and vulnerability 
to relapse following withdrawal is proposed 
to be the result of neuroadaptive processes 
within the central nervous system, lead-
ing to impairment in the mechanisms that 
mediate positive reinforcement and the 
emergence of affective changes (Weiss et al., 
2001). A plethora of gene changes develop 
in the brain during chronic use or absti-
nence, which are related to the glutamate/
corticoids, CREB/ERK, and NfκB pathways 
(Nestler, 2005; Li et al., 2008). Regardless 
the substance, a specific set of genes 
(Adora2a, Cnr1, Drd1, GPR88, Pde10a, 
Arpp21, Fam40b, Hpca, and Bc111b; mostly 
belonging to a huntingtin-centered path-
way) were downregulated in the abstinent 
brain (Kalivas and Volkow, 2005; Le Merrer 
et al., 2012), hence possibly contribute to 
the negative affect characterizing protracted 
abstinence. Not surprisingly, these neuroad-
aptations, which occur during the addiction 
process, have been associated with multiple 
neuropsychiatric disorders (de Lecea et al., 
2012).
Chronic stress increases the risk of 
depression, and is well known to increase 
relapse to drug seeking behavior (Bruchas 
et al., 2010). Depressive symptoms were 
suggested to be associated with absti-
nence-induced alterations in response to 
negative distracters (Froeliger et al., 2012). 
Findings suggest that the severity of depres-
sion symptoms are an important predic-
tor of psychosocial treatment efficacy for 
cocaine dependence and, hence, underline 
the importance of adequately addressing 
depression symptoms to improve treatment 
outcomes (Stulz et al., 2011).
Serotonergic dysregulation in depression 
and addiction comorbidity was suggested as 
a novel target for the treatment of addiction 
and the prevention of drug relapse (Kirby 
et al., 2011). A few randomized clinical tri-
als support the use of some antidepressant 
medications for combined cocaine depend-
ence and depression (Rounsaville, 2004). 
Nonetheless, at the current stage of evidence, 
data do not unambiguously support the effi-
cacy of antidepressants in the treatment of 
substance abuse/dependence (Pani et al., 
2011). Notably, most negative results came 
from studies that evaluated selective seroto-
nin reuptake inhibitors (SSRIs), while most 
positive results were found using norepi-
nephrine/dopamine-reuptake-inhibitors, 
such as desipramine or bupropion. Although 
psychiatric symptoms are the prime motive 
of addicts requesting treatment, they are 
not always the expression of an associated 
mental disorder. Indeed, the presence of 
depressive/anxious symptomatology in the 
clinical presentation appears to be unneces-
sarily related to “dual diagnosis” (i.e., addic-
tion and a mental illness). High-frequency 
abusers demonstrate an associated increased 
hypothalamic-pituitary-adrenal (HPA) axis 
activity, a characteristic stress response, to 
drug-cue exposure (Koob and Zorrilla, 
2010). The role of the norepinephrine sys-
tem in stress is well known, and its involve-
ment in the mechanisms/potentiation of 
substance abuse has been explored (Belujon 
and Grace, 2011). Therefore, we suggest that 
noradrenergic antidepressants are effective 
in the treatment of substance relapse, since 
they initially control the stress circuit, and 
secondarily ease the depressive symptoms.
There is a preponderance of evidence 
that abuse of substances is parallel with 
stress disorders (Lu et al., 2003; Koob and 
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Zorrilla, 2010; Sinha, 2011; Moeller, 2012), 
and anxiogenic effects of abstinence from 
substances of abuse is dependent on the 
period of the withdrawal. The adminis-
tration of anxiolytic agents, such as pro-
pranolol and buspirone or the 5-HT3 
receptor antagonist ondansetron, after an 
abstinence period, reversed the anxiogenic 
effect induced by nicotine, alcohol, cocaine, 
and opiates (Costall and Naylor, 1992; de 
Oliveira Citó Mdo et al., 2012).
Several neuropeptides, including cor-
ticotrophin-releasing hormone, neuro-
peptide Y, hypocretin/orexin, nociceptin/
orphanin have been shown to be stress-
related. Not surprisingly, they also play a 
pivotal role in addiction, mediating the neg-
ative affect associated with stress (Boutrel 
and de Lecea, 2008; Bruijnzeel, 2012). 
Endogenous opioid-neuropeptides, such as 
β-endorphin, dynorphin, enkephalin, and 
others, have been shown to play a major 
role in substance reinforcement (Tang et al., 
2005; Roth-Deri et al., 2008; Merenlender-
Wagner et al., 2009; Wee and Koob, 2010).
Herein we wish to present a new piece to 
this puzzle, suggesting two putative candi-
dates: the opioid neuropeptide β-endorphin 
and the neurosteroid dehydroepiandros-
terone (DHEA), both shown to modulate 
mood and addiction.
β-endorphin is an endogenous opioid 
produced mainly in the arcuate nucleus of 
the hypothalamus, and released, in part, in 
the nucleus accumbens (NAc). β-endorphin 
induces euphoria and has rewarding and 
reinforcing properties (Roth-Deri et al., 
2008). Consequently, it was demonstrated 
that cocaine induces dopamine-1-receptor 
dependent β-endorphin release in the NAc 
(Roth-Deri et al., 2008). Moreover, mice 
lacking β-endorphin demonstrated atten-
uation in cocaine-induced conditioned 
place preference (Marquez et al., 2008). 
β-endorphin binds with high affinity to 
μ- and δ-opioid receptors, while its affin-
ity to the κ-opioid receptor is lower (Akil 
et al., 1984).
Using opioid receptor antagonists, several 
studies support a role for the μ-opioid type 
receptor in cocaine addiction in humans 
(Ghitza et al., 2010) and animal models 
(Kreek et al., 2009; Simmons and Self, 
2009). Some studies showed that extended 
access to cocaine self-administration was 
associated with increased activity of the 
κ-opioid system or its endogenous agonist, 
dynorphin, in rats (Wee and Koob, 2010). 
κ-opioid receptor activation decreases 
acquisition or maintenance of cocaine, 
ethanol, morphine, and heroin by lowering 
their reinforcing/rewarding effects (Xi et al., 
1998; Logrip et al., 2008; Wee et al., 2009). 
However, during lower sub-threshold doses 
of cocaine and morphine during mainte-
nance, or abstinence following long access 
to cocaine, κ-opioid receptor activation 
facilitates substance self-administration or 
reinstatement, possibly through aversive-
like and stress-like effects (Kuzmin et al., 
1997; Wee and Koob, 2010). There is also 
some evidence for the involvement of the 
δ-opioid receptor in reward and addiction, 
but the studies are equivocal. Some have 
shown that non-peptidic δ-opioid receptor 
agonists elicit reward (Longoni et al., 1998), 
but some reported negligible abuse-related 
effects (Negus et al., 1998). The selective 
δ-opioid receptor antagonist naltrindole 
decreased responding for cocaine in rats, 
regardless of the schedule of reinforce-
ment (Reid et al., 1995). Conversely, others 
(de Vries et al., 1995) reported that only a 
high dose of naltrindole, which decreased 
locomotor activity, attenuated cocaine self-
administration. Intra-accumbal infusion of 
this δ-opioid receptor antagonist decreased 
cocaine self-administration, while adminis-
tration into the VTA significantly increased 
cocaine-maintained responding (Ward 
and Roberts, 2007). Some demonstrated 
that withdrawal from cocaine, resulted in 
increased anxiety and depression, accompa-
nied the desensitization of δ-opioid recep-
tor function. Furthermore, cocaine-induced 
anxiety- and depressive-like behaviors were 
reversed by the δ-opioid receptor agonist 
SNC80 (Perrine et al., 2008).
Previous studies reported an attenuated 
β-endorphin response during ethanol or 
nicotine relapse. One study examined the 
extent to which β-endorphin response 
to stress is associated with early smoking 
relapse. The authors found that smokers who 
relapsed exhibited attenuated β-endorphin 
response to stressors, compared to those 
who maintained abstinence over the same 
period (Shaw and al’Absi, 2008). Moreover, 
smokers who underwent weekly exercise ses-
sions had higher β-endorphin plasma levels 
and demonstrated a reduced smoking rate 
(Leelarungrayub et al., 2010). In another 
study, withdrawal from ethanol consump-
tion led to decreased β-endorphin plasma 
levels. Chronic treatment with acamprosate, 
which increases β-endorphin plasma con-
centrations, caused a significant reduction 
in ethanol intake (Zalewska-Kaszubska 
et al., 2008).
Preliminary results elucidate a novel role 
for β-endorphin in incubation of cocaine 
craving, a model that evaluates abuse-
related drug effects a long time after forced 
abstinence (Figure 1A). During the sati-
ated state, β-endorphin levels correspond 
to substance self-administration. Associated 
cues throughout short-term withdrawal 
trigger elevated β-endorphin release 
(Roth-Deri et al., 2008). Throughout long-
term abstinence, cues are unable to elicit 
enough β-endorphin release, concurrently 
with drug craving. Interestingly exogenous 
β-endorphin negated the heightened crav-
ing during long-term abstinence by acting 
on the δ-opioid-like receptor (unpublished 
results). Therefore, restoring abstinence-
induced deficits in β-endorphin levels may 
be an important factor in preventing crav-
ing and maintaining abstinence.
We suggest that anxious-like and impul-
sive responses are linked to the compulsive 
seeking behavior observed after abstinence 
from substance abuse, through the δ-opioid 
receptor. By applying δ-opioid receptor ago-
nists, we may bypass the lower efficacy of 
opioid-like receptor activity in the absti-
nence phase. Accordingly, this could cause 
a decrease in craving, simultaneously with 
decreased anxiety-like and depressive-like 
behaviors during extinction response.
Another candidate for intervention in 
substance abuse and relapse is DHEA, a 
natural steroid produced from cholesterol 
by the adrenal glands. DHEA is also pro-
duced in the gonads, adipose tissue, and the 
brain. It is structurally similar to, and is a 
precursor of, androstenedione, testosterone, 
and estrogens (Yadid et al., 2010).
Studies indicate that DHEA administra-
tion improves memory and cognitive pro-
cessing; acts as a growth hormone in helping 
neurons grow new dendrites and controls 
levels of the stress hormone cortisol (Flood 
et al., 1988; Ulmann et al., 2009; Yadid 
et al., 2010). In healthy men and women, 
it was found that DHEA supplementation 
improved mood and sense of well being, 
including better quality of sleep, increased 
energy, relaxation, and higher capability of 
handling stress (Morales et al., 1994). Long-
term treatment has been shown to  modulate 
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These suggested candidates may rep-
resent a hallmark of drug abstinence and 
an adaptive mechanism in coping with 
a history of substance abuse disorders 
(Figure 1D). Prospective prolongation of 
DHEA and β-endorphin function may 
result in protracted drug withdrawal.
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